Avernus Pharma

Avernus Pharma is a specialty pharmaceutical company based in the United Kingdom that focuses on the development of treatments for rare and orphan diseases. The company primarily targets metabolic and neurological disorders, with a specific emphasis on lysosomal storage diseases such as Niemann-Pick disease type C and Gaucher disease. Avernus utilizes drug repurposing and innovative formulation technologies to improve the efficacy and safety profiles of existing compounds. Their lead program, AVR-001, is designed to address the significant unmet medical needs of patients suffering from progressive neurodegenerative conditions. The company aims to provide accessible and effective therapeutic options for small patient populations globally. By focusing on value-added medicines, Avernus seeks to accelerate the clinical development timeline for critical orphan indications.